February 27, 2017 / 9:13 PM / 9 months ago

Perrigo to sell Tysabri's royalty stream to Royalty Pharma-sources

Feb 27 (Reuters) - Drugmaker Perrigo Co Plc said on Monday it has agreed to sell the royalty stream from its multiple sclerosis drug Tysabri to privately held Royalty Pharma for up to $2.85 billion.

The deal comprises of $2.2 billion in cash at closing and up to $650 million in potential milestone payments, according to a statement by Perrigo, which confirmed an earlier Reuters report about the agreement. (Reporting by Carl O‘Donnell and Greg Roumeliotis in New York; editing by Diane Craft)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below